Jianghua Qiao

Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial

Zhenzhen Liu, Chengzheng Wang, Xiuchun Chen et al. · European Journal of Cancer · 2022 · 44 citations · Full text

Medicine, Oncology, Pharmacology +17

ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis

Lina Wang, Yibing Chen, Yanjun Mi et al. · Biochemical and Biophysical Research Communications · 2020 · 42 citations

Life Sciences, Molecular Biology, Oncology +11

NR5A2 synergizes with NCOA3 to induce breast cancer resistance to BET inhibitor by upregulating NRF2 to attenuate ferroptosis

Jianghua Qiao, Yibing Chen, Yanjun Mi et al. · Biochemical and Biophysical Research Communications · 2020 · 34 citations

Life Sciences, Molecular Biology, Oncology +12

HN1L promotes migration and invasion of breast cancer by up‐regulating the expression of HMGB1

Dechuang Jiao, Jingyang Zhang, Ping Chen et al. · Journal of Cellular and Molecular Medicine · 2020 · 33 citations · Full text

Medicine, Molecular Biology, Oncology +16

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

Xiuchun Chen, Dechuang Jiao, Jianghua Qiao et al. · The Lancet Oncology · 2024 · 33 citations

Medicine, Oncology, Pharmacology +16